

Roche's obesity drug enicepatide posted 22.5% weight loss in 48 weeks, landing squarely in Zepbound territory and turning Roche from a latecomer into a legitimate contender. The real question: can it compete with what Lilly and Novo are cooking up next?
Two years ago, Roche spent $2.7 billion to acquire a small company called Carmot Therapeutics. The pitch: a promising obesity drug that could compete with the biggest names in pharma. Wall Street was skeptical. Roche had tried the GLP-1 game before and failed with a drug called taspoglutide. Why would this time be different?
Well, now we have the answer. At the American Diabetes Association's 2026 Scientific Sessions, Roche revealed that its once-weekly injectable, enicepatide, helped patients lose 22.5% of their body weight in just 48 weeks. More than a quarter of patients on the highest dose shed at least 30%.
For context, that puts enicepatide in the same weight-loss tier as Eli Lilly's Zepbound, the current gold standard. And it does it in roughly half the time that Zepbound's pivotal trials ran.
Enicepatide is what's called a dual GLP-1/GIP receptor agonist. Think of it like a key that fits two different locks in your body's appetite and metabolism system, instead of just one. Wegovy (Novo Nordisk's blockbuster) only turns one lock: GLP-1. Zepbound turns both, which is partly why it produces better weight loss.
But Roche's drug has a twist. Enicepatide was specifically engineered to activate those receptors through a particular signaling pathway (cAMP) while avoiding a different one (beta-arrestin) that tends to cause the receptor to shut down over time. Imagine a light switch that stays on instead of burning out after repeated flipping. That's the theory, anyway, and the 48-week results suggest it's working.
The Phase 2 trial enrolled 469 adults with obesity or overweight who also had a weight-related health condition. Patients received once-weekly injections across five different dose groups, with the highest dose at 24 mg. At 48 weeks, Roche reported something notable: weight loss was still continuing with no signs of a plateau.
That last detail matters. A lot. Most obesity drugs hit a ceiling where the body adapts and weight loss stalls. If enicepatide can keep the curve bending downward beyond 48 weeks, the final numbers could get even more impressive.

The FDA just went nuclear on compounded GLP-1 knockoffs, naming Hims & Hers and threatening seizures and injunctions. The multi-billion-dollar gray market for cheap Ozempic alternatives is about to get a lot smaller, and the fallout is hitting stocks, patients, and Big Pharma's bottom line all at once.


Join thousands of biotech professionals who start their day with our free, daily briefing.
Let's put the scoreboard up, keeping in mind these are cross-trial comparisons (different patients, different conditions, different timeframes).
Wegovy (semaglutide, Novo Nordisk) delivered about 13.7% to 15% weight loss in its pivotal obesity trials over 68 to 72 weeks. In a direct head-to-head trial called SURMOUNT-5, Zepbound beat Wegovy by a wide margin: 20.2% versus 13.7% at 72 weeks.
Zepbound (tirzepatide, Eli Lilly) has shown up to roughly 22.5% weight loss at its highest doses in earlier trials over about 72 weeks. Those are considered best-in-class results.
Enicepatide's 22.5% at 48 weeks is therefore right in Zepbound's neighborhood, and it got there faster. That's a significant signal, even with all the caveats about comparing different trials. It clearly outpaces Wegovy and looks competitive with (or possibly better than) Zepbound on a time-adjusted basis.
Analysts are taking notice, but nobody's handing Roche the crown just yet. RBC analyst Trung Huynh noted that Roche's drug and other rivals' candidates are "comparable to currently marketed treatments" on weight loss and side effects, but said they "cannot match Lilly's next-generation products" like retatrutide, a triple agonist showing up to 28.7% weight loss in its Phase 3 trials.
That's the fundamental tension. Roche isn't just racing against today's drugs; it's racing against tomorrow's. Lilly has orforglipron, an oral GLP-1 pill that received FDA approval in 2026. It also has retatrutide, which hits three receptors instead of two. Novo Nordisk is pushing CagriSema, a GLP-1 plus amylin combination that's already been filed with the FDA.
The obesity drug market could exceed $100 billion annually within the next decade. But being third or fourth to market with a competitive-but-not-superior drug is a very different business than being first. Roche knows this, which is why it isn't betting on enicepatide alone.
Roche has assembled what it calls a five-asset obesity franchise, and it's building the whole ecosystem at once.
Beyond enicepatide, there's CT-996, an oral GLP-1 candidate also from the Carmot acquisition. There's petrelintide, a long-acting amylin analog licensed from Zealand Pharma in a deal worth up to $5.3 billion. And there's emugrobart, a drug developed by Chugai Pharmaceutical in collaboration with Roche, designed to preserve lean muscle mass during weight loss, which addresses one of the biggest complaints about current GLP-1 therapies: patients lose muscle along with fat.
The strategy is combinations. Roche plans to use enicepatide as the "backbone" and layer other drugs on top. A combination trial pairing enicepatide with petrelintide is expected to begin in 2026. The idea is that amylin works through a completely different mechanism, potentially boosting weight loss while reducing the nausea that plagues current GLP-1 drugs.
Roche has also poured about $700 million into a new manufacturing facility in North Carolina, specifically for injectable obesity drugs. That's a clear signal: this isn't a science experiment anymore. They're building for commercial scale.
Phase 3 trials for enicepatide are slated to begin in the first half of 2026. The company has publicly stated its goal of becoming a top-three obesity company before 2030.
That's ambitious for a company that, until 2024, didn't even have an obesity drug in its pipeline. But the 22.5% number changes the math. It transforms Roche from a hopeful latecomer into a legitimate contender with Phase 3 data that could make or break its candidacy.
The obesity drug wars are turning into pharma's version of the streaming wars: too many well-funded players chasing the same massive audience, each convinced their content (or in this case, their molecule) is the one that will win. Lilly and Novo built the market. Roche, Amgen, Viking, and Pfizer all want a piece. With over 193 obesity drugs now in development globally, the field is getting absurdly crowded.
But crowded markets still produce winners. And Roche just proved it belongs in the conversation.
Eli Lilly's retatrutide slashed sleep apnea severity by 60.6% in a Phase 3 trial, posting numbers that appear to top its own FDA-approved Zepbound. The obesity drug wars just expanded well beyond the bathroom scale.